← Back to Search

Novel Lighting for Fall Prevention in Dementia

N/A

Waitlist Available

Led By Sheryl Zimmerman, PhD

Research Sponsored by University of North Carolina, Chapel Hill

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at study completion (one year)

Awards & highlights

Study Summary

This trial will test lights that outline doorframes to reduce falls in dementia patients in assisted living homes.

Who is the study for?

This trial is for assisted living residents with dementia who try to get out of bed, are not wheelchair-bound, blind, on hospice care, or expected to die/transfer within the study year. They must live alone in a room but can share a bathroom.Check my eligibility

What is being tested?

The study tests if special lights around doorframes can reduce nighttime falls in people with dementia. It's a one-year crossover trial where participants experience both the new lighting and regular conditions at different times.See study design

What are the potential side effects?

Since this intervention involves lighting changes rather than medication, side effects may include discomfort from the light or dissatisfaction with the system but no medical side effects are anticipated.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at study completion (one year)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at study completion (one year)

This trial's timeline: 3 weeks for screening, Varies for treatment, and at study completion (one year) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Falls incidence density ratio

Trial Design

4Treatment groups

Experimental Treatment

Group I: Lighting Sequence 4: LLCCExperimental Treatment2 Interventions

In this arm, the participant will receive the novel lighting condition (L) for the first two quarters (180 days) and then crossover to the control lighting condition (C) for the last two quarters (180 days). Q1 - Novel lighting Q2 - Novel lighting Q3 - Control lighting Q4 - Control lighting

Group II: Lighting Sequence 3: LCCLExperimental Treatment2 Interventions

In this arm, the participant will receive the novel lighting condition (L) for the first quarter (90 days) and then crossover to the control lighting condition (C) for the next two quarters (180 days) and finally crossover again to the novel condition (L) for the last quarter (90 days). Q1 - Novel lighting Q2 - Control lighting Q3 - Control lighting Q4 - Novel lighting

Group III: Lighting Sequence 2: CLLCExperimental Treatment2 Interventions

In this arm, the participant will receive the control lighting condition (C) for the first quarter (90 days) and then crossover to the novel lighting condition (L) for the next two quarters (180 days) and finally crossover again to the control condition (C) for the last quarter (90 days). Q1 - Control lighting Q2 - Novel lighting Q3 - Novel lighting Q4 - Control lighting

Group IV: Lighting Sequence 1: CCLLExperimental Treatment2 Interventions

In this arm, the participant will receive the control lighting condition (C) for the first two quarters (180 days) and then crossover to the novel lighting condition (L) for the last two quarters (180 days). Q1 - Control lighting Q2 - Control lighting Q3 - Novel lighting Q4 - Novel lighting

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor

1,508 Previous Clinical Trials

4,190,435 Total Patients Enrolled

5 Trials studying Aging

5,624 Patients Enrolled for Aging

National Institute on Aging (NIA)NIH

1,675 Previous Clinical Trials

28,020,495 Total Patients Enrolled

160 Trials studying Aging

75,617 Patients Enrolled for Aging

Sheryl Zimmerman, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

3 Previous Clinical Trials

4,960 Total Patients Enrolled

3 Trials studying Aging

4,960 Patients Enrolled for Aging

Media Library

Control Lighting Condition Clinical Trial Eligibility Overview. Trial Name: NCT05973448 — N/A

Aging Research Study Groups: Lighting Sequence 3: LCCL, Lighting Sequence 1: CCLL, Lighting Sequence 2: CLLC, Lighting Sequence 4: LLCC

Aging Clinical Trial 2023: Control Lighting Condition Highlights & Side Effects. Trial Name: NCT05973448 — N/A

Control Lighting Condition 2023 Treatment Timeline for Medical Study. Trial Name: NCT05973448 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still capacity to include individuals in this clinical trial?

"According to clinicaltrials.gov, the recruitment phase for this trial has ended; it was initially announced on August 1st 2023 and edited lastly on July 31st 2023. Even though no new participants are being sought, there remain 988 other trials currently recruiting patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Nightlight Falls Prevention Study

2023. "The Nightlight Falls Prevention Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05973448.